Over 2 decades ago, the idea for a polypill emerged as a plausible solution to reduce the global burden of cardiovascular disease (CVD) in low- and middle-income countries.1 Although with imperfect implementation and real-world challenges, a polypill is available outside the US.
The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with cardiometabolic syndrome at baseline, a speaker…
Watch Dr Aseem Malhotra’s Shocking Exposé on Pharma Accountability
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes…
Sobrevivir a la muerte súbita sin secuelas: RCP y desfibrilación aumentan las posibilidades. Nuevo post del blog “Salud y Prevención”.
This multicenter cohort study develops and assesses the validity of a deep learning model for predicting immune checkpoint inhibitor response in patients with advanced non−small…
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver lesions, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), that may further progress…
Most tissues have the capacity for endogenous lipid synthesis. A crucial foundational pathway for lipid synthesis is de novo lipid synthesis (DNL), a ubiquitous and…
We’re stuck in a vicious cycle. Hospital beds are full. Over 12% of hospital inpatients no longer meet the criteria to be there.12 This has…
AbstractBackground and Aims. Identifying the haemodynamic mechanism of autonomic syncope is the essential pre-requisite for effective and personalized ther
View the JACC: Case Reports landing page, presenting the most recent and relevant articles on cardiovascular case reports.
